This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-30 and is reviewed periodically as new material appears.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
A22, also known as S-(3,4-dichlorobenzyl) isothiourea, is a chemical compound with antibiotic activity. It is colorless, hygroscopic, and light-sensitive. A22 acts as a reversible inhibitor of the bacterial cell wall protein MreB, causing bacterial rod-shaped cells to form coccoid cells. The antibiotic activity of A22 has been studied primarily in Pseudomonas aeruginosa. However, A22 does not seem to be useful as an antibiotic in humans due to its cytotoxic and genotoxic effects on human peripheral blood mononuclear cells (PBMCs). Despite its cytotoxic effects in human cells, A22 has been used as a research tool to investigate the bacterial cytoskeleton. A22 binds directly to the actin homolog MreB in its nucleotide-binding pocket, blocking simultaneous ATP binding. As a consequence, A22 inhibits MreB polymerization and thus disrupts the cytoskeleton of bacteria, causing defects of morphology and chromosome segregation.
Michel Gondry was working on a film adaptation in early 2011, with Steve Golin and Steve Zaillian producing. In 2014, however, Gondry told French outlet Telerama (via Jeux Actu) that he was no longer working on the project and explained: "The book is brilliant, but it's good as a literary work. Having tried to adapt it with several screenwriters, ... at the moment I don't feel up to doing it. It doesn't have the dramatic structure that would make it a good film. I received a script that disheartened me a bit, and that was it. It was a dream, but in life you can't always have what you want."
=== Canine osteoarthritis === CBD's ability to help regulate the endocannabinoid system and reduce the release of excitatory neurotransmitters could result in a retrograde inhibitory signal that lessens chronic pain responses. Studies in dogs with chronic pain associated with osteoarthritis showed an increase in level of activity in animals receiving CBD-rich food supplements.
Hughes Helicopters was a major manufacturer of military and civilian helicopters from the 1950s to the 1980s. The company began in 1947, as a unit of Hughes Aircraft, then was part of the Hughes Tool Company after 1955. It became the Hughes Helicopter Division, Summa Corporation in 1972, and was reformed as Hughes Helicopters, Inc. in 1981. However, throughout its history, the company was informally known as "Hughes Helicopters". It was sold to McDonnell Douglas in 1984 and made a subsidiary under the name McDonnell Douglas Helicopter Systems, which was later renamed MD Helicopters when McDonnell Douglas merged with Boeing.
Sources: en.wikipedia.org
Moscow is first mentioned in chronicles in the year 1147, as part of the principality of Rostov-Suzdal, which emerged from the disintegration of Kievan Rus'. Moscow was referred to as a meeting place for Yuri Dolgorukiy and Sviatoslav Olgovich. At the time, it was a minor town on the western border of the principality. The importance of Moscow increased significantly during the second half of the 12th century, and the town was converted into a fortified gorod (stronghold) during the 1150s, when the first walls of the Kremlin were built. During the Mongol invasions of 1237–1238, Moscow was sacked following the destruction of Ryazan. The first prince of Moscow was Daniel, the youngest son of Alexander Nevsky. In 1263, Daniel was given Moscow as an otchina (hereditary land), where he established a local branch of Rurikid princes. Two chronicles refer to Mikhail Khorobrit as "Mikhail of Moscow" during the mid-13th century, but Daniel is generally considered to be the first prince of Moscow. On Mikhail's death in 1248—if it is assumed that an appanage principality was created (as a grant to a younger child of a monarch)—Moscow reverted as an escheat (where the state takes ownership of "unowned" land) to the grand prince of Vladimir. Until 1271, the principality was ruled by the governors of Daniel's uncle Yaroslav, who was given Tver as an appanage. Daniel is first mentioned in chronicles in the year 1282, when he participated in a feudal war between his two older brothers.
Acupuncture is a substantial part of traditional Chinese medicine (TCM). Early acupuncture beliefs relied on concepts that are common in TCM, such as a life force energy called qi. Qi was believed to flow from the body's primary organs (zang-fu organs) to the "superficial" body tissues of the skin, muscles, tendons, bones, and joints, through channels called meridians. Acupuncture points where needles are inserted are mainly (but not always) found at locations along the meridians. Acupuncture points not found along a meridian are called extraordinary points and those with no designated site are called A-shi points. In TCM, disease is generally perceived as a disharmony or imbalance in energies such as yin, yang, qi, xuĕ, zàng-fǔ, meridians, and of the interaction between the body and the environment. Therapy is based on which "pattern of disharmony" can be identified. For example, some diseases are believed to be caused by meridians being invaded with an excess of wind, cold, and damp. In order to determine which pattern is at hand, practitioners examine things like the color and shape of the tongue, the relative strength of pulse-points, the smell of the breath, the quality of breathing, or the sound of the voice. TCM and its concept of disease does not strongly differentiate between the cause and effect of symptoms. Acupuncture was and is practiced differently by various Chinese philosophical schools, and differs from acupuncture from Korea and Japan.
== SoBe Beverages == Upon his departure from the NFL, Bello took a position as VP Marketing with Brooklyn, New York-based Ferolito, Vultaggio and Sons, makers of AriZona iced tea. At AriZona he joined a former Pepsi colleague Mike Schott, then COO of AriZona Beverages. After four months he left AriZona to create his own beverage company in partnership with Tom Schwalm that became the South Beach Beverage Company, named after the trendy South Beach area of Miami. The new company, based in Norwalk, Connecticut, marketed so-called "New Age" beverages—exotic juice blends and ready-to-drink iced teas—but faced formidable competition from its predecessors, including Snapple, Mystic, Nantucket Nectars and AriZona. South Beach needed a point of differentiation in the marketplace, so Bello added trace elements of various herbs and nutrients—such as ginseng, ginkgo biloba, guarana, carnitine, Echinacea, yohimbe, taurine and praline—and promoted their benefits beyond hydration. He launched a "3G" line of drinks, which included supposed energy boosters like ginseng, ginkgo biloba and guarana. He also expanded the brand's iced tea portfolio to include more exotic offerings such as Black Tea, Oolong Tea (with bee pollen), Green Tea (with Echinacea) and Red Tea (with selenium).
== Diagnosis == In addition to hematoxylin-eosin staining to evaluate histological changes, lesion characteristics, genetic history, and special histochemical staining to highlight the composition of connective tissue nevus for differentiation, these tests are necessary for the diagnosis of connective tissue nevus.
As of January 2018, neither the plant nor its alkaloids were listed in any of the Schedules of the United Nations Drug Conventions. In 2021, the World Health Organization's Executive Committee on Drug Dependency investigated the risks of kratom and declined to recommend a critical review of it. The committee, however, recommended kratom be kept "under surveillance".
Sources: en.wikipedia.org
=== PCNA-PIDDosome === In addition to the signaling pathways previously discussed, PIDD1 is essential for translesion DNA synthesis (TLS), which allows for DNA extension across damaged regions in response to UV radiation. Within the nucleus, PIDD1 has been observed to associate with critical components of the replication machinery, such as proliferating cell nuclear antigen (PCNA) and replication factor C subunits RFC4 and RFC5, forming a complex referred to as the PCNA-PIDDosome. These proteins were identified as interacting partners of overexpressed PIDD1 through mass spectrometry analysis. PCNA functions as a DNA-sliding clamp that depends on replication factor C (RFC) for its correct positioning on DNA and is crucial for loading DNA polymerases during the replication process. Additionally, PCNA is essential for various DNA repair activities. Importantly, the interactions among [8PIDD]]1, PCNA, and RFC5 are facilitated by their ZU5 domains. As a result, this complex can only form with full-length PIDD1 or, due to the limited availability of full-length PIDD1 and the preferential nuclear localization of its primary autoprocessing product, with PIDD-C.
== Prevention == The primary prevention of bronchiolitis obliterans in people who have received either lung transplant or HSCT therapy is immunosuppression. In regards to post lung transplantation, the combination of calcineurin inhibitor combined with a purine synthesis inhibitor and a glucocorticoid is the general regimen used. People also have a baseline post-transplant lung function testing done in order to determine if their lung function is declining over time. People who are post-HSCT their immunosuppressive regimen typically includes methotrexate in combination with a calcineurin inhibitor to prevent GVHD, a risk factor for developing bronchiolitis obliterans.
=== Inhibition of protein synthesis === The inhibition of protein synthesis is mediated through aminoglycosides' energy-dependent, sometimes irreversible binding, to the cytosolic, membrane-associated bacterial ribosome (image at right). (Aminoglycosides first cross bacterial cell walls—lipopolysaccharide in gram-negative bacteria—and cell membranes, where they are actively transported.) While specific steps in protein synthesis affected may vary somewhat between specific aminoglycoside agents, as can their affinity and degree of binding, aminoglycoside presence in the cytosol generally disturbs peptide elongation at the 30S ribosomal subunit, giving rise to inaccurate mRNA translation and therefore biosynthesis of proteins that are truncated, or bear altered amino acid compositions at particular points. Specifically, binding impairs translational proofreading leading to misreading of the RNA message, premature termination, or both, and so to inaccuracy of the translated protein product. The subset of aberrant proteins that are incorporated into the bacterial cell membrane may then lead to changes in its permeability and then to "further stimulation of aminoglycoside transport". The amino sugar portion of this class of molecules (e.g., the 2-deoxystreptamine in kanamycins, gentamicins, and tobramycin, see above) are implicated in the association of the small molecule with ribosomal structures that lead to the infidelities in translation (ibid.). Inhibition of ribosomal translocation—i.e., movement of the peptidyl-tRNA from the A- to the P-site—has also been suggested.
Dysphoric milk ejection reflex (D-MER) is a condition in which breastfeeding women develop negative emotions that begin just before the milk letdown reflex and last less than a few minutes. It may recur with every letdown, including unexpected letdowns when the baby is not feeding. It presents as an emotional reaction but may also produce physical feelings such as nausea. It is different from postpartum depression and other known psychological conditions. A 2019 study reported a prevalence rate of 9.1%. As of 2021, very little research has been done, and many health care providers and lactation practitioners remain barely able to recognize the syndrome. An October 2021 review of literature published to that date suggested that the lack of up-to-date information "makes it necessary to educate mothers because educated mothers are usually better at handling postpartum situations if they are prepared in advance." There is as yet no medication to treat the symptoms although women have reported that they have found it of benefit to learn that they are not alone and that the symptoms were not "just in their head".
==== Psychotherapy ==== Psychotherapy for individuals with AN is challenging as they may value being thin and may seek to maintain control and resist change. Initially, developing a desire to change is fundamental. There is no strong evidence to suggest one type of psychotherapy over another for treating anorexia nervosa in adults or adolescents.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.